These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 11365545)

  • 21. Selected highlights from the 5th Conference on Retroviruses and Opportunistic Infections.
    Bartnof HS
    BETA; 1998 Apr; ():49-56. PubMed ID: 11365269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fifth Conference on Retroviruses & Opportunistic Infections. Interview by Ron Baker.
    Follansbee S; Deeks S; Bartnoff H
    Newsline People AIDS Coalit N Y; 1998 Mar; ():7-14. PubMed ID: 11367453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drifting agenda for federal treatment research.
    Huff B
    GMHC Treat Issues; 2001 May; 15(5):1-4. PubMed ID: 11548299
    [No Abstract]   [Full Text] [Related]  

  • 25. What's new, what's next?
    Fakuda D
    Posit Dir News; 1998; 10(2):1, 3-7, 10. PubMed ID: 11365547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antivirals update.
    Proj Inf Perspect; 1998 Dec; (26):8-10. PubMed ID: 11366501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [HIV infections: mortality reduced only in developed countries].
    Wehr A
    Dtsch Med Wochenschr; 1999 May; 124(18):A8-9. PubMed ID: 10356577
    [No Abstract]   [Full Text] [Related]  

  • 28. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B
    Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moving forward: a treatment overview from the 12th World AIDS Conference.
    Agosto M
    Newsline People AIDS Coalit N Y; 1998 Sep; ():6-11. PubMed ID: 11367497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
    Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
    [No Abstract]   [Full Text] [Related]  

  • 32. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 33. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
    Schooley RT; Clumeck N; Haubrich R; Thompson M; Danner SA; van Der Ende ME; Sereni D; Antunes F; Blake D; Myers RE; Tisdale M; Millard J; Mustafa N; Nacci P
    Antivir Ther; 2001 Jun; 6(2):89-96. PubMed ID: 11491421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
    Hanna L
    BETA; 1998 Oct; ():9-13. PubMed ID: 11365999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New expanded access drugs for use in combination therapy.
    Newsline People AIDS Coalit N Y; 1998 Dec; ():22-3. PubMed ID: 11367085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of the naive patient.
    Bartlett JG
    Hopkins HIV Rep; 1999 Mar; 11(2):1, 10-1. PubMed ID: 11366244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
    Martínez E; Arnaiz JA; Podzamczer D; Dalmau D; Ribera E; Domingo P; Knobel H; Riera M; Pedrol E; Force L; Llibre JM; Segura F; Richart C; Cortés C; Javaloyas M; Aranda M; Cruceta A; de Lazzari E; Gatell JM;
    N Engl J Med; 2003 Sep; 349(11):1036-46. PubMed ID: 12968087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous drug users risk group should also benefit from simpler highly active antiretroviral therapy.
    Parienti JJ
    AIDS; 2002 Oct; 16(15):2097; author reply 2098. PubMed ID: 12370515
    [No Abstract]   [Full Text] [Related]  

  • 39. Don't mix Sustiva with Fortovase.
    Posit Aware; 1998; 9(5):17. PubMed ID: 11365885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dupont pharmaceuticals study 006 for Sustiva.
    Bartlett JG
    Hopkins HIV Rep; 1998 Sep; 10(5):1. PubMed ID: 11365772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.